EP3064496A4 - Amorphous allisartan isoproxil, preparation method therefor, and pharmaceutical composition containing amorphous allisartan isoproxil - Google Patents

Amorphous allisartan isoproxil, preparation method therefor, and pharmaceutical composition containing amorphous allisartan isoproxil Download PDF

Info

Publication number
EP3064496A4
EP3064496A4 EP14856893.4A EP14856893A EP3064496A4 EP 3064496 A4 EP3064496 A4 EP 3064496A4 EP 14856893 A EP14856893 A EP 14856893A EP 3064496 A4 EP3064496 A4 EP 3064496A4
Authority
EP
European Patent Office
Prior art keywords
allisartan isoproxil
amorphous allisartan
preparation
pharmaceutical composition
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14856893.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3064496A1 (en
Inventor
Duanming TAN
Jun OU
Guanhao Ye
Shui BU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharmaceuticals Co Ltd filed Critical Shenzhen Salubris Pharmaceuticals Co Ltd
Publication of EP3064496A1 publication Critical patent/EP3064496A1/en
Publication of EP3064496A4 publication Critical patent/EP3064496A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP14856893.4A 2013-11-01 2014-10-29 Amorphous allisartan isoproxil, preparation method therefor, and pharmaceutical composition containing amorphous allisartan isoproxil Withdrawn EP3064496A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310535073 2013-11-01
PCT/CN2014/089775 WO2015062498A1 (zh) 2013-11-01 2014-10-29 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物

Publications (2)

Publication Number Publication Date
EP3064496A1 EP3064496A1 (en) 2016-09-07
EP3064496A4 true EP3064496A4 (en) 2017-04-12

Family

ID=53003359

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14856893.4A Withdrawn EP3064496A4 (en) 2013-11-01 2014-10-29 Amorphous allisartan isoproxil, preparation method therefor, and pharmaceutical composition containing amorphous allisartan isoproxil

Country Status (7)

Country Link
US (1) US9670184B2 (ru)
EP (1) EP3064496A4 (ru)
JP (1) JP2016535767A (ru)
KR (1) KR20160068979A (ru)
CN (3) CN111018841B (ru)
RU (1) RU2668267C2 (ru)
WO (1) WO2015062498A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115974848B (zh) * 2017-10-24 2024-04-02 深圳信立泰药业股份有限公司 阿利沙坦酯钙盐晶型及含有所述钙盐晶型的药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1988090A1 (en) * 2006-02-20 2008-11-05 Shanghai Allist Pharmaceutical., Inc. Imidazol-5-carboxylic acid derivatives, preparation methods and use therrof
EP2157089A1 (en) * 2007-06-07 2010-02-24 Shanghai Allist Pharmaceutical., Inc. The therapeutic uses of imidazol-5-carboxylic acid derivatives
EP2213669A1 (en) * 2007-10-11 2010-08-04 Shanghai Allist Pharmaceuticals, Inc. Crystalline imidazol-5-carboxylic acid derivate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
AU2003209669A1 (en) * 2003-02-25 2004-09-17 Hetero Drugs Limited Amorphous form of losartan potassium
CN101195615B (zh) * 2006-12-06 2013-03-27 深圳市信立泰资产管理有限公司 咪唑-5-羧酸衍生物的盐、制备方法及其药物组合物
CN101214242A (zh) 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
CN101367795B (zh) * 2007-08-17 2012-05-02 上海艾力斯生物医药有限公司 一种咪唑-5-羧酸衍生物及其制备方法
CN101596189A (zh) * 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
CN103012377A (zh) * 2011-09-27 2013-04-03 江苏艾力斯生物医药有限公司 一种咪唑-5-羧酸酯的重结晶方法
CN103965171A (zh) * 2014-04-30 2014-08-06 上海艾力斯医药科技有限公司 一种阿利沙坦酯的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1988090A1 (en) * 2006-02-20 2008-11-05 Shanghai Allist Pharmaceutical., Inc. Imidazol-5-carboxylic acid derivatives, preparation methods and use therrof
EP2157089A1 (en) * 2007-06-07 2010-02-24 Shanghai Allist Pharmaceutical., Inc. The therapeutic uses of imidazol-5-carboxylic acid derivatives
EP2213669A1 (en) * 2007-10-11 2010-08-04 Shanghai Allist Pharmaceuticals, Inc. Crystalline imidazol-5-carboxylic acid derivate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HANCOCK B C ET AL: "What is the true solubility advantage for amorphous pharmaceuticals?", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, vol. 17, no. 4, 1 April 2000 (2000-04-01), pages 397 - 404, XP009086748, ISSN: 0724-8741, DOI: 10.1023/A:1007516718048 *
See also references of WO2015062498A1 *

Also Published As

Publication number Publication date
US9670184B2 (en) 2017-06-06
US20160251338A1 (en) 2016-09-01
CN109320501A (zh) 2019-02-12
JP2016535767A (ja) 2016-11-17
WO2015062498A1 (zh) 2015-05-07
CN111018841A (zh) 2020-04-17
CN111018841B (zh) 2023-04-07
KR20160068979A (ko) 2016-06-15
CN109320501B (zh) 2021-06-01
RU2668267C2 (ru) 2018-09-28
EP3064496A1 (en) 2016-09-07
CN104610232A (zh) 2015-05-13
RU2016119149A (ru) 2017-12-04
CN104610232B (zh) 2019-09-20

Similar Documents

Publication Publication Date Title
EP2947084B8 (en) Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof
EP3040331A4 (en) Tetrahydrocyclopentapyrrole derivative and preparation method therefor
EP3059238A4 (en) Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
IL266300B (en) Antecedents of glutarimide, their use, a pharmaceutical preparation based on them and methods for producing antecedents of glutarimide
HK1222563A1 (zh) 藥物組合物、製備及其用途
EP3048146A4 (en) Film-forming composition and film-forming method using same
EP3022250A4 (en) Metal-organic materials and method for preparation
EP3087987A4 (en) Pharmaceutical composition containing palonosetron
EP2990039A4 (en) Solid pharmaceutical composition
EP3012256A4 (en) HETEROCYCLIC BENZIMIDAZOLE-2-PIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARATION AND USE THEREOF
EP3037099A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
EP3029043A4 (en) Tricyclic benzoxaborole compound, preparation method therefor, and use thereof
EP3090746A4 (en) Pharmaceutical composition not containing antioxidant and preparation method therefor
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3072895A4 (en) Phillygenol sulphate and derivative thereof, and preparation method and application thereof
EP3065712A4 (en) Microparticles, methods for their preparation and use
EP3062803A4 (en) Herbal composition, process for its preparation and use thereof
EP2950646A4 (en) AGROCHEMICAL COMPOSITION, PROCESS FOR PREPARATION AND USE THEREOF
EP3078659A4 (en) 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3135666A4 (en) (s)-oxiracetam crystal form iii, preparation method therefor, and application thereof
EP3090728A4 (en) Oral composition
EP3090732A4 (en) Pharmaceutical composition containing clomipramine and preparation method therefor
EP3072896A4 (en) Taxane compound, and preparation method and use thereof
EP3003298A4 (en) Anti-fibrogenic compounds, methods and uses thereof
EP2985338A4 (en) Fragrance composition and method for producing same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170315

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 403/10 20060101AFI20170309BHEP

Ipc: A61K 31/4178 20060101ALI20170309BHEP

Ipc: A61P 9/12 20060101ALI20170309BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180305

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180717